Asthma patients treated with Breo Ellipta (also known as Relvar Ellipta) had greater improvement in asthma control compared to usual care, according to results from the Salford Lung Study (SLS) reported by GlaxoSmithKline and Innoviva Inc.

As part of the Phase 3, open-label, randomized study, over 4,000 asthma patients were treated either with Breo Ellipta 100/25mcg or 200/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’) or usual care, which included ICS administered as monotherapy or as ICS/LABA combinations. In the usual care arm, 36% of patients were on an ICS alone, and 64% were on an ICS/LABA combination at the time of commencing study medication.

For the primary effectiveness analysis, at 24 weeks a significantly higher percentage of patients with uncontrolled asthma and initiated on treatment with FF/VI achieved better control of their asthma (71%)  measured by the Asthma Control Test (ACT), compared with patients continuing usual care treatment (56%).

Improvement was defined as an ACT total score ?20 or an increase from baseline of ?3. Statistically significant findings were also seen at 12, 40 and 52 weeks.

“Despite medical advances, more than half of patients with asthma continue to experience poor control and significant symptoms. The primary endpoint of this study showed that patients initiated with [Breo Ellipta] treatment had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care in this study in everyday clinical practice,” said Eric Dube, senior vice president and head, Global Respiratory Franchise, GSK. “This study has been a tremendous partnership effort between healthcare professionals, patients, academics and GSK and we would like to thank everyone who has helped to make this unique study possible.”